Reimbursementintelligence - reimbursementintelligence.com - Reimbursement Intelligence
General Information:
Latest News:
American Health & Drug Benefits, July 2013 1 Aug 2013 | 11:13 pm
Rapid Expansion of New Oncology Care Delivery Payment Models: Results from a Payer Survey
Quoted in MMM Rare Diseases Ebook, July 2013 24 Jul 2013 | 07:26 pm
Orphan Drug Marketing: Data and expert insight for physician, patient and payer outreach
Quoted in Marin Independent Journal, April 2013 22 Apr 2013 | 07:17 pm
BioMarin seeks approval to market another drug for rare disease
Why can’t we be on the same team? 19 Apr 2013 | 06:44 pm
For a while, I’ve heard the complaint that data and information from pharmaceutical manufacturers can’t be trusted because their motives directly conflict with those of health care providers. I am cal...
Pharma Is Hamstrung By An Out-dated Product-Centric Worldview 5 Apr 2013 | 11:48 pm
Healthcare manufacturers sell products. Period. And that’s a problem. Providers and payers look to create health –and, increasingly, reap higher rewards for delivering better health. Products, be they...
Pharma Is Hamstrung By An Out-dated Product-Centric Worldview 5 Apr 2013 | 11:48 pm
Healthcare manufacturers sell products. Period. And that’s a problem. Providers and payers look to create health –and, increasingly, reap higher rewards for delivering better health. Products, be they...
Quoted in Managed Care, March 2013 29 Mar 2013 | 12:35 am
Beware the Increasing Cost And Number of Orphan Drugs
Quoted in Managed Care, March 2013 29 Mar 2013 | 12:35 am
Beware the Increasing Cost And Number of Orphan Drugs
Double Dipping: Do you double dip? 19 Mar 2013 | 07:30 pm
We all know the politically correct answer is “no, of course not!” so why has it become a growing issue for pharmaceutical companies? The Affordable Care Act (ACA) expansion of qualified 340B entities...
Double Dipping: Do you double dip? 19 Mar 2013 | 07:30 pm
We all know the politically correct answer is “no, of course not!” so why has it become a growing issue for pharmaceutical companies? The Affordable Care Act (ACA) expansion of qualified 340B entities...
